new research link , page-3

I also like how RM Reasearch stated on page#1 of their report that;

" Strong Investment Thesis Going Forward: Multiple Catalysts and Upside Opportunities - A Rare Find - The stock will remain on the radar of many investors due to strong newsflow These could include commercial launch of Lung Dx and Cxbladder, sales numbers from hair loss business, potential update on the therapeutic programs, and any additional commercial and licensing deals. In addition, we view diabetic nephropathy program and future partnerships in molecular diagnostics as an upside to our current target price, with strong IP around midkine at the core of the business. Preclinical data collected to date identify MK as a key molecule in diabetic nephropathy and suggest that MK accelerates the intracellular signaling network evoked by hyperglycemia in diabetic nephropathy. We believe anti-midkine antibodies could offer superior clinical profile over the key current therapies that we evaluated (see inside note for our detailed analysis on that opportunity)."


Very good report, and supports the momentum building in the sp.